SCHEMBL6058397

SCHEMBL6058397

CCOC(=O)c1ccc2nc(NC(=O)Oc3ccccc3)sc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.71
NPC1 O15118 11/20 0.71
RAB9A P51151 10/20 0.71
STAT1 P42224 1/20 0.71
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 4/20 0.67
KMT2A Q03164 3/20 0.64
ACP1 P24666 1/20 0.64
TP53 P04637 3/20 0.64
HSD17B10 Q99714 2/20 0.64
HPGD P15428 2/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
MAPT P10636 5/20 0.63
USP2 O75604 2/20 0.63
GAA P10253 2/20 0.62
ALPL P05186 1/20 0.61
SCD O00767 1/20 0.55
PIK3CA P42336 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6057541 0.83 NPC1 (1.00) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL18585932 0.81 NPC1 (0.77) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL6057632 0.81 LCK (0.72) KMT2A
SCHEMBL14808429 0.80 SMN1; SMN2 (0.77) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL11303998 0.80 NPC1 (0.80) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL4746072 0.80 NPC1 (0.77) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL28878441 0.78 NPC1 (0.74) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL29973978 0.78 NPC1 (0.74) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1
SCHEMBL13189051 0.78 KMT2A (0.74) SMN1; SMN2NPC1RAB9AALDH1A1KMT2A
SCHEMBL6057496 0.78 NPC1 (0.73) SMN1; SMN2NPC1RAB9ASTAT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1037632-B1 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-01-11 EP disclosed
US-6825355-B2 FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE BRISTOL-MYERS SQUIBB CO. 2004-11-30 US disclosed